Clinical trial · Interventional
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer
NCT01237678CI-TRIAL-00031263terminatedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was stopped early due to lack of efficacy signal and safety concerns
Summary
Brief summary (as posted)
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin and Etoposide | Drug | — | UNRESOLVED |
| IMGN901 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- IMGN901 with carboplatin and etoposide
- description
- Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
- interventionNames
- Drug: IMGN901
- type
- ACTIVE_COMPARATOR
- label
- Carboplatin and Etoposide
- description
- Patients will receive Carboplatin and etoposide for up to 6 cycles.
- interventionNames
- Drug: Carboplatin and Etoposide
Primary outcomes (3)
- measure
- Occurrence of Dose Limiting Toxicities (DLT)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be 18 years old * Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease * ECOG performance status of 0, 1, or 2 * No prior systemic chemotherapy for the treatment of SCLC Exclusion Criteria: \- Pregnant or lactating females
References
Publications (0)
Data not yet available
No reference posted for this study.